Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy

Daniel W Isenbarger; Steven M Kent; Patrick G O'Malley

doi:10.1016/j.amjcard.2003.08.059

Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy

Am J Cardiol. 2003 Dec 15;92(12):1454-8. doi: 10.1016/j.amjcard.2003.08.059.

Authors

Daniel W Isenbarger¹, Steven M Kent, Patrick G O'Malley

Affiliation

¹ Cardiovascular Service, Walter Reed Army Medical Center, Washington, DC, USA. daniel.isenbarger@na.amedd.army.mil

PMID: 14675586
DOI: 10.1016/j.amjcard.2003.08.059

Abstract

Multiple small studies of oral N-acetylcysteine for prevention of contrast nephropathy have been performed, demonstrating variable efficacy. We performed a meta-analysis of the randomized clinical trials to clarify the degree of benefit.

Publication types

Meta-Analysis

MeSH terms

Acetylcysteine / therapeutic use*
Acute Kidney Injury / chemically induced*
Acute Kidney Injury / prevention & control*
Antioxidants / therapeutic use*
Contrast Media / adverse effects*
Creatinine / blood
Humans
Randomized Controlled Trials as Topic

Substances

Antioxidants
Contrast Media
Creatinine
Acetylcysteine